HRH1 and neoplasm: To evaluate the inhibitory effect of HRH1 on the tumor microenvironment (TME) in PDAC, we investigated the effects of Az, a Food and Drug Administration (FDA) approved HRH1 antagonist, as well as its synergistic effect on αPD-1 treatment (Fig. 2A).